Antiarrhythmic effects of acute betablockade with atenolol on supraventricular tachycardias at rest and during exercise
- PMID: 7206601
- DOI: 10.1007/BF01477354
Antiarrhythmic effects of acute betablockade with atenolol on supraventricular tachycardias at rest and during exercise
Abstract
In a total of 18 patients, 7 females and 11 male patients with ages ranging from 23 to 70 years (mean: 45.5 +/- 14.5) diagnostic His bundle studies incorporating programmed atrial and ventricular pacing for the induction of tachycardias was performed before and after betablockade with the cardioselective betablocking agent atenolol, in a dose of 5 mg given iv. over 3 to 5 minutes. In 7 patients the pacing procedure could be repeated following ergometric exercise in order to evaluate the influence of a raised sympathetic tone on the conditions initiating paroxysmal tachycardias. At rest, atenolol prevented the pacing induced tachycardias (20 dysrhythmias in 18 patients) in 3/5 individuals with Wolff-Parkinson-White (WPW)-syndrome, in 4/6 cases with atrial tachycardias, in 4/6 patients presenting atrial flutter, in 2/2 cases developing AV-nodal tachycardias and in 1/1 individual with ventricular tachycardia. Thus, in 13 out of 19 (68%) supraventricular dysrhythmias patients benefitted from atenolol by preventing or controlling the tachycardia. Ergometric exercise changed the tachycardia or echo zone in 5/8 arrhythmias after betablockade when compared to the controls before administration of atenolol (3/5 improvement by narrowing of the tach- or echo zone, 1/5 prevention of tachycardia, 1/5 impairment due to widening of the tachycardia zone). Considering only the prevention of tachycardias, the antiarrhythmic potency of atenolol was improved in one patient with pacing induced flutter and impaired in one individual with a WPW syndrome, by ergometric exercise. These results suggest that atenolol seems to provide a good antiarrhythmic action, especially in supraventricular tachycardias, and that an increased sympathetic tone during exercise may modify the antidysrhythmic strength of betablockade.
Similar articles
-
[Electrophysiologic effect of sotalol in supraventricular tachycardias].Z Kardiol. 1985 Sep;74(9):506-11. Z Kardiol. 1985. PMID: 4060828 German.
-
Effect of almokalant, a selective potassium channel blocker, on the termination and inducibility of paroxysmal supraventricular tachycardias: a study in patients with Wolff-Parkinson-White syndrome and atrioventricular nodal reentrant tachycardia. Almokalant PSVT Study Group.J Cardiovasc Pharmacol. 1995 Aug;26(2):198-206. doi: 10.1097/00005344-199508000-00004. J Cardiovasc Pharmacol. 1995. PMID: 7475043 Clinical Trial.
-
Effects of almokalant, a class III antiarrhythmic agent, on supraventricular, reentrant tachycardias. Almokalant Paroxysmal Supraventricular Tachycardia Study Group.Cardiovasc Drugs Ther. 1997 Jul;11(3):499-508. doi: 10.1023/a:1007761825414. Cardiovasc Drugs Ther. 1997. PMID: 9310280 Clinical Trial.
-
Using the right drug: a treatment algorithm for regular supraventricular tachycardias.Eur Heart J. 1997 May;18 Suppl C:C27-32. doi: 10.1093/eurheartj/18.suppl_c.27. Eur Heart J. 1997. PMID: 9152672 Review.
-
Pharmacologic management of supraventricular tachycardias in children. Part 1: Wolff-Parkinson-White and atrioventricular nodal reentry.Ann Pharmacother. 1997 Oct;31(10):1227-43. doi: 10.1177/106002809703101016. Ann Pharmacother. 1997. PMID: 9337449 Review.
Cited by
-
Electrophysiological effects of cardioselective and non-cardioselective beta-adrenoceptor blockers with and without ISA at rest and during exercise.Br J Clin Pharmacol. 1982;13(Suppl 2):285S-293S. doi: 10.1111/j.1365-2125.1982.tb01926.x. Br J Clin Pharmacol. 1982. PMID: 6125178 Free PMC article.